Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

Pasithea begins PAS-004 Phase 1/1b NF1 trial in Australia, with U.S. and S. Korea sites planned. First dosing set for Q2 2025. 48.5% R&D refund expected.